Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
← catalyst calendarNCT05925803 · readout in 140 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
314actual
Sites
150
Countries
Austria, Belgium, Canada +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-08 | actual | When the study began enrolling |
| Primary completion | 2027-01-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-05 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Sclerosis
- Scleroderma
Interventions
- Combination product: Anifrolumab (blinded) — also filed as Treatment arm (blinded)
- Drug: Placebo (blinded) — also filed as Placebo arm (blinded)
- Combination product: Anifrolumab (unblinded, open label) — also filed as Treatment arm (not blinded)
Primary outcome
what the primary-completion date above is the date OFNumber of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25)
measured at Week 52
Publications
- PMID 41217519 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed